Article Abstract

Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis

Authors: Derek Nichols, Theresa A. Boyle, David Noyes, Kujtim Latifi, Vladimir Feygelman, Isabel Jackson, Zeljko Vujaskovic, Scott Antonia, Bradford A. Perez


Outcomes for patients with inoperable locally advanced non-small cell lung cancer (LA-NSCLC) are poor, with a median survival of about 2 years (1) and a 5-year survival of about 10–15% following diagnosis, even among patients with good performance status at presentation (2). Despite these poor outcomes, conventional radiation therapy (RT) with chemotherapy remains the standard of care.